Search

Displaying results 5241 - 5250 of 6949 in total
  1. Drug

    Eftansomatropin alfa

    go.drugbank.com/drugs/DB18460
    Investigational

    [L48275] It is under investigation for the treatment of growth hormone deficiency.

  2. Drug

    rAAV9-CMV-hNAGLUop

    go.drugbank.com/drugs/DB33959
    Experimental

    rAAV9-CMV-hNAGLUop is a biologic drug. rAAV9-CMV-hNAGLUop is under investigation in clinical trial NCT07818759 (Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS)

  3. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU). … enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for

  4. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  5. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for

  6. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  7. Drug

    7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE

    go.drugbank.com/drugs/DB07512
    Experimental

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  9. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

    Categories: Sphingosine-1-phosphate (S1P) receptor modulators
  10. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.